PubMed Health⌕ Search

PubMed · 598083

Periosteal chondroma.

Abstract

Periosteal chondroma is an uncommon benign cartilagenous lesion, and its importance lies primarily in its characteristic radiographic and pathologic appearance which should be of assistance in the differential diagnosis of eccentric lesions of bones. The pathologist must be aware of this tumour because at a histologic level, it may closely resemble a more ominous cartilagenous lesion. He can exclude this lesion in a differential diagnosis of a primary cartilagenous bone neoplasm by familiarity with the clinical and radiological appearance of the lesion. In all cases reported so far, treatment has been that of wide local excision. There are no recorded cases of metastases in follow-up periods ranging up to 8 years after surgery. In those cases where local recurrences were reported, inadequate initial excision is the admitted cause, and subsequent re-excision led to complete eradication of the residual tumour.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V L Fornasier, D McGonigal. 1977. Periosteal chondroma.. https://pubmed.ncbi.nlm.nih.gov/598083/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Hematometrocolpos in an adolescent female treated for pelvic Ewing sarcoma.

Radiation therapy is often used to achieve local control of pelvic Ewing sarcoma in children. The effects of radiation on the female reproductive tract have been well documented in adults with gynecological malignancies, but the long-term consequences of pelvic radiation in pre-pubertal or adolescent girls are not as well described. We report a case of hematometrocolpos developing in an adolescent previously treated with chemotherapy and radiation therapy for pelvic Ewing sarcoma. We describe the clinical presentation, radiographic features, gross pathology, treatment strategies, outcome, as well as putative predisposing factors and preventative interventions.

Bone Neoplasms↗

Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.

BACKGROUND: Prostate cancer (PCa) and bone cell interactions are critical in the metastatic phase. Kallikrein 4 (KLK4/hK4) is expressed in both PCa and mineralized tissues. We determined if KLK4/hK4 expression was associated with, and influenced by, the bone environment of metastatic PCa. METHODS: Immunohistochemistry, in vitro co-culture, cell migration, and attachment assays. RESULTS: hK4 was localized to tumor cells and osteoblasts in bone metastases. KLK4/hK4 increased in LNCaP and PC3 cells co-cultured with SaOs2 cells; SaOs2 KLK4/hK4 was unchanged. Co-culture did not affect cell proliferation but altered alkaline phosphatase activity/mRNA levels in SaOs2 cells. KLK4-transfected PC3 cells had increased migration towards SaOs2 conditioned medium and greater attachment to the bone-matrix proteins, collagens I and IV. CONCLUSIONS: hK4 expression and interaction with both tumor cells and osteoblasts suggests a role for hK4 in PCa bone metastasis. Whether this observation is unique to bone metastasis or reflects a role for hK4 in PCa metastasis generally is yet to be established.

Bone Neoplasms↗